Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.56
+1.8%
$2.18
$1.09
$7.22
$181.13M2.981.41 million shs955,346 shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$0.47
-1.6%
$0.56
$0.34
$1.86
$40.34M1.78724,315 shs373,196 shs
Instil Bio, Inc. stock logo
TIL
Instil Bio
$29.23
+0.0%
$26.48
$10.80
$92.00
$197.33M2.16188,621 shs87,676 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$1.16
+6.9%
$0.83
$0.36
$4.01
$188.24M3.072.95 million shs1.65 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-3.46%-2.33%+18.40%+62.99%-60.28%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-2.04%-5.64%-9.76%-15.34%-72.73%
Instil Bio, Inc. stock logo
TIL
Instil Bio
+8.22%+2.85%+31.44%-15.06%+109.46%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-4.42%0.00%+61.05%+105.05%-59.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.4403 of 5 stars
3.14.00.00.02.71.70.0
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.836 of 5 stars
3.53.00.00.02.71.70.6
Instil Bio, Inc. stock logo
TIL
Instil Bio
3.625 of 5 stars
3.54.00.00.03.33.30.6
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
2.9455 of 5 stars
3.51.00.00.02.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.25
Hold$8.00213.11% Upside
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3.00
Buy$3.75701.28% Upside
Instil Bio, Inc. stock logo
TIL
Instil Bio
3.00
Buy$119.00307.12% Upside
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
3.00
Buy$6.25441.13% Upside

Current Analyst Ratings Breakdown

Latest IPSC, CCCC, TNYA, and TIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
8/27/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00 ➝ $125.00
8/27/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
8/22/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/15/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00 ➝ $125.00
8/7/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/5/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00 ➝ $125.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.58M5.11N/AN/A$2.45 per share1.04
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$6.59M6.14N/AN/A$2.43 per share0.19
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/A$19.50 per shareN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$0.61 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$126.57M-$0.29N/AN/AN/A-19.10%-11.53%-6.94%11/4/2025 (Estimated)
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$111.13M-$0.96N/AN/AN/AN/A-93.83%-75.66%11/5/2025 (Estimated)

Latest IPSC, CCCC, TNYA, and TIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.38-$0.38N/A-$0.38$0.03 millionN/A
8/13/2025Q2 2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$1.72-$3.24-$1.52-$3.24N/AN/A
8/7/2025Q2 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million
8/6/2025Q2 2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.06
5.06
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
10.72
10.72
Instil Bio, Inc. stock logo
TIL
Instil Bio
0.64
14.97
14.97
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
6.00
6.00

Institutional Ownership

CompanyInstitutional Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
Instil Bio, Inc. stock logo
TIL
Instil Bio
60.56%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%

Insider Ownership

CompanyInsider Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
5.00%
Instil Bio, Inc. stock logo
TIL
Instil Bio
46.50%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
48.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.17 million64.96 millionOptionable
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
17086.39 million82.07 millionOptionable
Instil Bio, Inc. stock logo
TIL
Instil Bio
4106.75 million3.61 millionNo Data
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
110162.98 million83.69 millionOptionable

Recent News About These Companies

Tenaya (TNYA) Q2 Loss Narrows 59%

New MarketBeat Followers Over Time

Media Sentiment Over Time

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$2.56 +0.05 (+1.79%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$0.47 -0.01 (-1.64%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Instil Bio stock logo

Instil Bio NASDAQ:TIL

$29.23 +0.01 (+0.03%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Tenaya Therapeutics stock logo

Tenaya Therapeutics NASDAQ:TNYA

$1.16 +0.08 (+6.94%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.